Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 131.37 |
---|---|
High | 134.33 |
Low | 129.41 |
Bid | 133.25 |
Offer | 133.75 |
Previous close | 130.39 |
Average volume | 944.77k |
---|---|
Shares outstanding | 123.68m |
Free float | 118.60m |
P/E (TTM) | -- |
Market cap | 16.59bn USD |
EPS (TTM) | -2.47 USD |
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
- Natera to Participate in Upcoming Investor Conferences
- Natera to Report its Third Quarter 2024 Results on November 12, 2024
- Natera to Present New Renasight Data at ASN Kidney Week 2024
- Court Orders Permanent Injunction Against NeoGenomics' Accused RaDaR Assay, as Case Enters New Phase
- Natera Announces Three New Signatera Publications; Includes Groundbreaking Overall Survival Data Published in Nature Medicine and also Released at ESMO
- First of its Kind Colorectal Cancer Data from Prospective GALAXY Study Released at ESMO; Demonstrates Signatera's Ability to Predict Overall Survival
- Natera to Present New Signatera™ Colorectal Cancer Data at ESMO Showing 10X Advantage in Overall Survival
- Natera to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
More ▼